Back to all products
| Factor XIII |
| FXIII-Inhibitors |
| Fibrin aggregation and clotting |
| FXIII Activity Assays |
| Fibrin clot degradation |
| Antibodies |
FXIII Activity Assays
FXIII-Assay Substance,
Abz-NE(CAD-DNP)EQVSPLTLLK-OH Art. No.
A101
Background info
Also suitable for TG1, TG2, TG3 and TG6
Molecular Formula
C80H123F3N20O27 (free base: C78H122N20O25)
Molecular Weight
1853.95 (free base: 1739.92)
Purity by HPLC
>95 % (HPLC)
Appearance
yellow solid
Solubility
50 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 10 mg (5.39 μmol) in 108 μl DMSO - dilute e.g. 10 μl of that stock solution (50 mM) with 9990 μl aqueous buffer to obtain a 50 μM solution. DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Pre-dissolve e.g. 10 mg (5.39 μmol) in 108 μl DMSO - dilute e.g. 10 μl of that stock solution (50 mM) with 9990 μl aqueous buffer to obtain a 50 μM solution. DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application
Kinetic measurement of transglutaminases
Storage
Store at -20°C, desiccate
Reference(s)
Oertel, K. et al. Anal. Biochem. 2007, 367, 152.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
Berny‐Lang, M.A. et al. J. Am. Heart Assoc. 2013, 2, e000026.
Schroeder, V. et al. Br. J. Haematol. 2015, 168, 757.
de Jager, M. et al. Neuropathol. Appl. Neurobiol. 2016, 42, 255.
Király, R. et al. Amino Acids 2016, 48, 31.
van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232.
Dodt, J. et al. Br. J. Haematol. 2016, 172, 452.
Chrobok, N.L. et al. PLoS ONE 2018, 13, e0209522.
Akbar, A. et al. J. Med. Chem. 2017, 60, 7910-7927.
Singh, S. et al. Int. J. Mol. Sci. 2019, 20, 2682.
Gates et al., Molecules 2023, 28:1634.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
Berny‐Lang, M.A. et al. J. Am. Heart Assoc. 2013, 2, e000026.
Schroeder, V. et al. Br. J. Haematol. 2015, 168, 757.
de Jager, M. et al. Neuropathol. Appl. Neurobiol. 2016, 42, 255.
Király, R. et al. Amino Acids 2016, 48, 31.
van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232.
Dodt, J. et al. Br. J. Haematol. 2016, 172, 452.
Chrobok, N.L. et al. PLoS ONE 2018, 13, e0209522.
Akbar, A. et al. J. Med. Chem. 2017, 60, 7910-7927.
Singh, S. et al. Int. J. Mol. Sci. 2019, 20, 2682.
Gates et al., Molecules 2023, 28:1634.
Note
The molecular weight was corrected to 1853.95, taking into account that A101 traps only one TFA counter ion instead of two counter ions as stated in PDS RN3.1 from 07 May 2014. The presence of one TFA counter ion is valid for all former batches, too.
Background: During the course of our continuous quality assurance process, Zedira developed a novel method to quantify the TFA counter ion content by using a 19F NMR method according to Little et al. (J. Pharm. Biomed. Anal. 2007, 43, 1324), based on an internal standard.
Please note that neither the synthesis and purification nor the product as such has been changed. Please consider the molecular weight correction if necessary.
Intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background: During the course of our continuous quality assurance process, Zedira developed a novel method to quantify the TFA counter ion content by using a 19F NMR method according to Little et al. (J. Pharm. Biomed. Anal. 2007, 43, 1324), based on an internal standard.
Please note that neither the synthesis and purification nor the product as such has been changed. Please consider the molecular weight correction if necessary.
Intended for research use only, not for use in human, therapeutic or diagnostic applications.
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation